Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
There is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one protocol in common use involves the use of intravesical gemcitabine instilled into the bladder during surgery and prior to entry into the bladder. There are barriers to the use of gemcitabine, especially at lower volume centers. Some evidence suggests that intravesical irrigation with sterile water has equivalent efficacy to intravesical chemotherapy in prevention of recurrent bladder cancer following transurethral resection of bladder tumors (TURBT). This study is intended to compare recurrence rates using intravesical gemcitabine (as a pseudo-standard of care) and continuous bladder irrigation with sterile water.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony biopsją rak górnych dróg moczowych z planem operacji ratującej (usunięcie części moczowodu lub nerki z moczowodu)
- •Wiek 18-90 lat
- •Spodziewana długość życia ponad 1 rok
- •Gotowość stosowania antykoncepcji lub abstynencji (dla kobiet mogących mieć dzieci i mężczyzn)
- •Zdolność zrozumienia informacji i chęć podpisania zgody na udział w badaniu
✗ Disqualifies
- •Wcześniejszy rak pęcherza moczowego lub nawrót w ostatnich 3 latach
- •Rak obustronny górnych dróg moczowych (chyba że druga strona była wolna od choroby przez ponad 3 lata)
- •Plan całkowitego usunięcia pęcherza
- •Mały pojemność pęcherza (poniżej 100 mL)
- •Alergia na gemcytabinę lub podobne substancje
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 90 Years
- Last updated (source)
- August 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Texas Southwestern Medical Center
Dallas, United States
Trial contact
Corey Nixon, MD
Phillip McDuffie, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.